Several submitters recommended that dental treatments can be integral to the clinical success of covered nephrology-related medical services including services received by beneficiaries who are immunocompromised by end-stage renal disease (ESRD), chronic kidney disease (CKD), other renal diseases, as well as kidney transplant candidates maintained on immunosuppressive medications
The revisions proposed at 414.1365(c)(3)(i) introductory text and additions proposed at paragraphs (c)(3)(i)(A) through (C) would require that an MVP Participant who reports an MVP, in the CY 2023 through 2024 performance periods/2025 through 2026 MIPS payment years, report one of the following: two medium-weighted improvement activities
We seek comment on this proposal to revise the sixth criterion of the definition of attribution-eligible beneficiary at 414.1305 to include a beneficiary who has at least one claim for a covered professional service furnished by an eligible clinician who is on the Participation List for the APM Entity (or by the individual eligible clinician, as applicable) at any determination date during the QP Performance Period
Does a DNA test show drugs
not maintained or updated to reflect current clinical guidelines, which are not reflective of a clinician's scope of practice
Therefore, when calculating Threshold Scores for QP determinations, we exclude from the list of attributed beneficiaries any beneficiaries who do not meet the criteria to be attribution-eligible beneficiaries at that point in time
